top of page
The Professional Network for Healthcare Experts
PureTech-Backed Celea Raises $180m to Challenge Established IPF Treatments
New funding will support a pivotal Phase III trial comparing deupirfenidone head-to-head with Roche’s Esbriet as competition intensifies in idiopathic pulmonary fibrosis.
nuaxia
Jul 73 min read
Celea Therapeutics Secures $180m to Advance Phase III IPF Programme
Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.
nuaxia
Jul 52 min read
bottom of page